In a phase I study in healthy volunteers (NCT01374503), ALX-0651 demonstrated appreciable CXCR4 targeting ability; however, the study and any subsequent investigations into ALX-0651 as an anti-cancer agent were halted due to an inability to outcompete other CXCR4 antibodies [209]. This evidence concerns the gene CXCR4 and cancer.